In a retrospective analysis of patients withMM, NHL, and Hodgkin disease undergoingstem cell mobilization with either chemotherapyplus G-CSF or G-CSF plus plerixafor, investigatorsfound there was no significant difference ineither the median total CD34+ cells/kg collectedor in the number of days required to reach a targetof 5 × 106 CD34+ cells/kg. The gene discussed is CSF3; the disease is non-Hodgkin lymphoma.